Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
about
Trial Watch: Proteasomal inhibitors for anticancer therapyPeripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
P2860
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Good clinical activity and fav ...... of relapsed multiple myeloma.
@ast
Good clinical activity and fav ...... of relapsed multiple myeloma.
@en
type
label
Good clinical activity and fav ...... of relapsed multiple myeloma.
@ast
Good clinical activity and fav ...... of relapsed multiple myeloma.
@en
prefLabel
Good clinical activity and fav ...... of relapsed multiple myeloma.
@ast
Good clinical activity and fav ...... of relapsed multiple myeloma.
@en
P2093
P2860
P356
P1476
Good clinical activity and fav ...... of relapsed multiple myeloma.
@en
P2093
Alessandro Corso
Cristiana Pascutto
Federica Cocito
Lara Pochintesta
Mario Cazzola
Silvia Mangiacavalli
P2860
P304
P356
10.1002/AJH.23358
P577
2012-12-08T00:00:00Z